Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition.
about
Autophagy limits activation of the inflammasomes.Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency.Apoptosis and non-alcoholic fatty liver diseases.Inflammasome: A Double-Edged Sword in Liver DiseasesAutophagy in Metabolic Age-Related Human Diseases
P2860
Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Ezetimibe ameliorates steatohe ...... NLRP3 inflammasome inhibition.
@en
Ezetimibe ameliorates steatohe ...... NLRP3 inflammasome inhibition.
@nl
type
label
Ezetimibe ameliorates steatohe ...... NLRP3 inflammasome inhibition.
@en
Ezetimibe ameliorates steatohe ...... NLRP3 inflammasome inhibition.
@nl
prefLabel
Ezetimibe ameliorates steatohe ...... NLRP3 inflammasome inhibition.
@en
Ezetimibe ameliorates steatohe ...... NLRP3 inflammasome inhibition.
@nl
P2093
P2860
P50
P1433
P1476
Ezetimibe ameliorates steatohe ...... NLRP3 inflammasome inhibition
@en
P2093
Bohkyung Kim
Hye Jin Wang
Jeong Eun Yoo
Kook Hwan Kim
Soo Hyun Kim
Young-Mi Song
P2860
P304
P356
10.1080/15548627.2017.1356977
P577
2017-09-21T00:00:00Z